Navigation Links
Sorrento Therapeutics Receives Frost & Sullivan's Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
Date:6/6/2013

tential bioequivalence (BE) to Abraxane® to get Cynviloq™ to the market quickly and at minimal cost using the FDA 505(b)(2) BE application pathway that allows companies to obtain FDA approval of new drug applications (NDAs) for reformulations of drugs with the same active ingredient.

"Sorrento is unique in its ability to potentially have an approved oncology product within the next few years using an abbreviated 505(b)(2) BE pathway at a fraction of the cost of what is spent by traditional drug development companies," noted Frost & Sullivan Industry Analyst Justin Collishaw . "Our independent analysis confirms that other competitors lack similar near-term approvable therapies, which may be able to generate revenues in the next three to four years."

Sorrento, through its IGDRASOL acquisition, also secured EU distribution rights, which give Sorrento the flexibility to form alliances with multinational companies seeking late-stage drug products to fill in gaps in their pipeline. In addition, Sorrento is moving forward in the field of true personalized medicine with the development of Therapeutic Drug Monitoring (TDM), which will complement and expand the Cynviloq™ franchise in the market.

Sorrento's next strength lies in its outstanding management team that boasts an impressive track record of long-term vision and timely execution. Such an industry-leading management team will help Sorrento's valuable products reach their full potential.

"Partnership with large pharma could accelerate Sorrento's development program and broaden its portfolio into inflammation and infectious diseases," noted Collishaw. "As a publicly traded company, Sorrento has the added advantage of access to the public investment market."

Sorrento is further consolidating its market position by targeting therapeutic areas with an unmet need. The company is selecting antibody candidates that have strong
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Awarded Third Phase I STTR Grant
2. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
3. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
6. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
7. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... PALO ALTO, Calif. , Aug. 1, 2014 /PRNewswire/ ... announced a partnership to expand awareness of proper nutritional ... CFChef Shares program. CFChef Shares will run from August ... CFChef program – an online resource for CF patients ... healthy diet by submitting recipes to the Chef4CF.com ...
(Date:8/1/2014)... Minn. , Aug. 1, 2014 ... medical technologies company, announced today that it has ... held manufacturer of cardiorespiratory diagnostic products based in ... MediSoft has served the European cardiorespiratory diagnostics market ... 2013 revenues of approximately €4.7 million ($6.3 million) ...
(Date:8/1/2014)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... study evaluating ISIS-SMN Rx in infants with spinal ... infant mortality. Isis plans to dose the first infant ... which time Isis will earn an $18 million milestone ... 3 study, ENDEAR, is the first of several planned ...
Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5
... UNION CITY, Calif., Sept. 9, 2011 Abaxis, Inc. ... analysis systems, announced today that Clint Severson, chairman and ... Annual Best Ideas Conference 2011 on Wednesday, September 14, ... held at The Omni Berkshire Place Hotel in New ...
... Inc. (" Valeant ") (NYSE/TSX:VRX), announced today that Valeant mailed ... ") its offer and take-over bid circular in connection with ... all of the outstanding common shares of Afexa (the " ... per Common Share. The Offer expires at 5:00p.m. ...
Cached Medicine Technology:Abaxis, Inc. to Present at CL King's 9th Annual Best Ideas Conference 2011 2Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 2Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 3Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 4
(Date:8/1/2014)... Diego School of Medicine report that dietary capsaicin ... activation of a receptor on cells lining the intestines ... risk of colorectal tumors. , The findings are published ... Journal of Clinical Investigation . , The receptor or ... neurons, where it acts as a sentinel for heat, ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, ... manufacturing jobs may have significantly less endurance than those who weigh ... people -- half were obese, half were of normal weight -- ... 60 percent longer. Obesity also was associated with less strength, ... older -- 50 to 65 years of age -- neither improved ...
(Date:8/1/2014)... Ohio In a first-of-its-kind study, researchers at University ... that lap infants may be at greater risk for ... pediatric medical emergencies on flights worldwide between January 2010 ... occurred in children under the age of 2. ... to characterize the rare event of an in-flight pediatric ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 As AndroGel ... the country, Ronald E. Johnson, Jr. has been appointed ... AndroGel and other testosterone medications. Since the Fall of ... P.S.C. have worked diligently to investigate and prosecute the ... embolisms, and blood clots as a result of taking ...
(Date:8/1/2014)... Texas (PRWEB) August 01, 2014 ... health coverage and healthcare reforms are boosting healthcare ... of medicines through discounts and increasing generic consumption ... at approximately 76.7 million in 2013, having grown ... 1.4%, from 2008. The implementation of the Health ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:New research characterizes in-flight pediatric deaths 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4
... , 221.10.254.64 COLUMBIA, Mo. Due to changing ... be screened for breast cancer with mammograms, many women ... years and older get a mammogram every year, but ... other year for women older than 50. A University ...
... to help oncologists keep up to date with the ... been launched by the European Society for Medical Oncology ... and news organization. OncologyPRO Oncology Professional ... -- integrating regularly updated oncology news, clinical research, biomarker ...
... An early phase multiple myeloma trial has unexpectedly ... in cells that affect its dose level in the ... Cancer Center Arthur G. James Cancer Hospital and ... conducted the study., Lenalidomide is an anti-inflammatory drug, and ...
... MONDAY, Aug. 8 (HealthDay News) -- Older patients with ... verbal memory impairment, a new study finds. Verbal ... compared heart failure severity and cognitive function -- including ... for potential heart transplantation. Heart failure severity was ...
... features of the influenza virus,s entry point into human ... flu vaccine to protect against a broad range of ... to develop, produce, and distribute a new vaccine for ... Stephen C. Harrison, PhD, chief of the Division of ...
... new source for sexual problems among middle-aged and older ... men,s closest friends. Cornell University and University of ... and the social networks shared by heterosexual men and ... betweenness." In such cases, a man,s female partner has ...
Cached Medicine News:Health News:Doctors, women should spend more time discussing mammograms 2Health News:OncologyPRO -- a revolutionary resource for oncologists 2Health News:Study urges caution with lenalidomide dosage 2Health News:Fine-tuning the flu vaccine for broader protection 2Health News:When a man's female partner becomes too buddy-buddy with his pals, his sex life may suffer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: